English
Specials
    Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    Loans
    Loans
    HomeNewsBusinessMoneycontrol ResearchGland Pharma’s new product play for FY22 holds a lot of promise

    Gland Pharma’s new product play for FY22 holds a lot of promise

    While the US market is still expected to clock 18-20 per cent growth for Gland Pharma in FY22, the company’s foray into non-US markets would accelerate growth in the medium term

    Anubhav Sahu
    July 22, 2021 / 19:11 IST
    Gland Pharma’s new product play for FY22 holds a lot of promise

    Gland Pharma Limited | The share price has surged 124 percent to 3,367.05 on July 1, 2021, from its issue price of Rs 1,500. It was listed on exchanges on November 20, 2020, with an issue size of Rs 6,480 crore.

    • PRO Panorama

      Moneycontrol Pro Panorama | Insuring tomorrow's borrowing

      Sep 12, 2025 / 02:41 PM IST

      In September 12 edition of Moneycontrol Pro Panorama: Indian IT is at a crossroads, don’t let the listless market force your han...

      Read Now
    • PRO Weekender

      Moneycontrol Pro Weekender | Blood Moon Rising: A Week That Exposed the Cracks in the Global System

      Sep 13, 2025 / 10:00 AM IST

      This week's convergence of protests, conflict and economic strain are symptoms of the unravelling of the global order

      Read Now
    Unlock This Article

    Are you a PRO subscriber? Sign In

    What Do You Get

    • Ad free Experience

      Seamless navigation, faster responses.

    • Expert Perspective

      Explore 230+ exclusive editorials every month

    • +

      Uncover Insights from World-Renowned Experts and Journalists

    • Actionable Insights

      40+ weekly investment ideas + 3 to 4 daily technical calls

    • Virtual Events

      Exclusive Live Webinars for Expert Trading & Investment Strategies!

    • Newsletters

      Stay ahead with daily and weekly insights

    View Offers

    Unlock exclusive discounts

    Disclosure & Disclaimer

    This Research Report / Research Recommendation has been published by Moneycontrol Dot Com India Limited (hereinafter referred to as “MCD”) which is a registered Investment Advisor under the Securities and Exchange Board of India (Investment Advisers) ...Read More